ABSTRACT-All-trans-retinoic acid (ATRA) is a derivative of vitamin A with antiproliferative properties. Endotoxin shock and subsequent immunosuppression (IS) by lipopolysaccharide (LPS) stimulates myelopoiesis with expansion of myeloidderived suppressor cells (MDSC). Since we have previously shown that ATRA reverses the IS state by decreasing functional MDSC, our aim was to investigate if ATRA was able to modulate MDSC generation by regulating myelopoiesis in murine hematopoietic organs. We found that ATRA administration in vivo and in vitro decreased the number of CD34þ precursor cells that were increased in IS mice. When we studied the cellular mechanisms involved, we did not find any differences in apoptosis of CD34þ precursors or in the differentiation of these cells to their mature counterparts. Surprisingly, ATRA decreased precursor proliferation, in vitro and in vivo, as assessed by a reduction in the size and number of colony forming units generated from CD34þ cells and by a decreased incorporation of 3 H-thymidine. Moreover, ATRA administration to IS mice decreased the number of MDSC in the spleen, with a restoration of T lymphocyte proliferation and a restitution of the histological architecture. Our results indicate, for the first time, a new use of ATRA to abolish LPS-induced myelopoiesis, affecting the proliferation of precursor cells, and in consequence, decreasing MDSC generation, having a direct impact on the improvement of immune competence. Administration of ATRA could overcome the immunosuppressive state generated by sepsis that often leads to opportunistic life-threatening infections. Therefore, ATRA could be considered a complementary treatment to enhance immune responses.
INTRODUCTION
Retinoids are natural derivatives, or synthetic analogs, of vitamin A involved in many important biological processes. Aberrant retinoid signaling mechanisms have been associated with cancer development in humans and animals (1) . Retinoids are being increasingly included in both chemopreventive and therapeutic schemes of various tumoral diseases (2) . In general, they are believed to inhibit carcinogenesis by blocking the promotion of already initiated or transformed cells by three mechanisms: induction of apoptosis, irreversible cell cycle arrest (cellular senescence), and induction of abnormal cells to differentiate back to normal (2, 3) . In particular, all-transretinoic acid (ATRA), the active derivative of vitamin A, has been extensively studied as an anticancer agent (2) . It has been shown that ATRA inhibits the growth of tumor cells by blocking the cell cycle (3). However, the effect of ATRA on normal myeloid cells is much less clear.
Sepsis is one of the oldest and most elusive syndromes in medical history. The mortality of sepsis still remains at about 20% to 30% in the United States (4) . Patients who survive the initial shock, mainly the pro-inflammatory, phase of sepsis are at risk of developing a state of immune suppression and become susceptible to nosocomial infections with organisms that are not typically pathogenic in immunocompetent hosts. In fact, secondary infections that develop due to post-sepsis immunosuppression are a major cause of death in patients with sepsis (5) . In this sense, the effects of ATRA on an immunosuppressed scenario due to infections have been less studied.
Immature myeloid-derived suppressor cells (MDSC) are a heterogeneous cell population consisting of myeloid progenitor cells, considered to be one of the major components of the immune suppressive network responsible for suppressing T cell responses in pathological conditions such as tumors (6) . More recently, expansion of MDSC has been described in acute and chronic inflammatory diseases including trauma, inflammation, burn, and autoimmune diseases (7) . In mouse, MDSC are identified by a Gr-1þ CD11bþ CD31þ phenotype and their expansion has been recently reported in spleen and lymph nodes from septic animals (8) , and in BM and lymph nodes from lipopolysaccharide (LPS)-induced immunosuppressed mice (9, 10) , as well as in blood from septic patients (11) .
Hematopoiesis is a hierarchical process in which hematopoietic stem cells (HSC) differentiate into progenitor cells (common lymphoid or common myeloid progenitors) that are capable of exponential proliferation as well as continuing the process of differentiation, accounting for repopulation of myeloid, lymphoid, and megakaryocyte/erythroid cells during normal replenishment (12) . CD34 has served as the most important marker for hematopoietic precursors and is present all along progenitors that give rise to myeloid cells (13) . Moreover, only CD34þ cells have the ability to form hematopoietic colonies in vitro, whereas no colonies are generated from CD34À cells at any developmental stage (14) .
After infections, in several inflammatory reactions and after LPS administration, there is an increased myelopoiesis in bone marrow (BM) and a subsequent cell precursor mobilization to peripheral blood to repopulate myeloid populations (12) . In this sense, an increase of CD34þ cells has been reported in septic patients and in cecum ligation and puncture mice (15) . As part of this CD34þ cell expansion, there is also an increase in MDSC population. Possibly developed as a normal regulatory mechanism to counteract a triggered immune response, MDSC generation in a dysregulated pathological scenario, such as sepsis, may be involved in the etiology of LPS-induced immunosuppression. In this sense, the reduction of this suppressive population has been shown to be beneficial in different experimental settings (7) . Moreover, direct suppressive activity of CD34þ cells has been reported as well. In sepsis, the presence of granulocyte colony stimulating factor is reported to mobilize a murine population of CD34þ cells endowed with potent immunosuppressive activity (16) . This population was shown to inhibit the alloreactive response in vitro and in vivo. Moreover, in patients with head and neck cancer, the presence of CD34þ cells suppressed functional competence of lymphocytes within the squamous cell carcinoma and inhibited their capacity to secrete interleukin-2 (17) . Altogether, these results support the idea that eliminating or reducing the increase of the CD34þ cell precursor population may contribute to an improved immunosuppressive state in sepsis.
Experimentally, repetitive inoculation of increasing doses of LPS to mice induces derangements in the inflammatory response and a state of adaptive immunosuppression (9, 18) , mimicking several clinical signs found in patients who develop immunosuppression after a septic episode (19) . Exposure to LPS has been considered the initial phase and one of the causes of the immunosuppression frequently observed in late sepsis. Using this model we and others have shown that mice develop a clear state of immunosuppression, as evidenced by an impaired antigen-specific antibody production, decreased T cell proliferation, lymphocyte depletion, increased of immature myeloid cells with suppressive functions, reduced ability to produce TNF-a and other cytokines in vitro, and induction of antiinflammatory mediators such as IL-10, transforming growth factor-beta, and glucocorticoids (9, 10, 18, 20) .
In a previous work, we have shown that ATRA administration to LPS-immunosuppressed mice was able to restore the number of different lymphocyte populations and reversed the inhibited MDSC-mediated T cell proliferation in lymph nodes (9) . Therefore, in this work, our aim was to address the question whether ATRA can affect LPS-induced myelopoiesis, regulating the number of immature MDSC and probably their generation, in order to reestablish the immunologic unbalance in immunosuppression. Elucidating this mechanism is critical not only for understanding the biology of ATRA effects on myeloid cells but also for assessing its potential use, together with other therapies, in post-sepsis immunosuppression. 
MATERIALS AND METHODS

Reagents
Experimental model of LPS-induced immunosuppression
BALB/c mice were bred in the animal facility of IMEX, Academia Nacional de Medicina, Buenos Aires. Male mice aged 2 to 3 month and weighing 20 g to 25 g were used throughout the experiments. They were maintained under a 12 h light-dark cycle at 22 AE 28C and fed with standard diet and water ad libitum. For all experiments, LPS-induced immunosuppression was developed by daily subcutaneous (s.c.) inoculation of increasing doses of LPS for a period of 15 days, as follows: two doses of 5, two doses of 10, two doses of 20, three doses of 50, and six doses of 100 mg/day/mouse. In in vivo experiments, concomitantly to LPS administration, another group of mice was daily inoculated via intraperitoneal (i.p.) either with vaseline (IS group), or ATRA (500 mg/day/ mouse, ISþA group). ATRA was obtained from commercial supply. The capsule content was removed in sterile conditions and the concentration adjusted with vaseline immediately before administration. Other groups of animals were given every day s.c. saline solution and i.p. vaseline (Control group), or s.c. saline solution and ATRA i.p. (ATRA group). The total number of animals per group was 8 or 12 according to each experiment. For experiments that the total number per group was 8, we performed two experimental repetitions with four animals in each group and for experiments that the total number per group was 12, we performed three experimental repetitions with four animals in each group (see legend to Figures 1-6) .
The experiments were conducted according to principles set forth in the Guide for the Care and Use of Laboratory Animals (21) , and the study was approved by the Animal Care and Use Committee of our Institution.
Cell tissue collection
The spleen and BM were removed from mice under sterile conditions, and single-cell suspensions were prepared by homogenization through a sterile stainless-steel mesh. To perform the experiments, the spleens were processed in 2 mL of medium RPMI-1640, 10% FCS, 0.1% 2-mercapoethanol, 1% Lglutamine, and 1% antibiotic-antimycotic (complete medium). After centrifugation, the cell suspension was collected. Femurs and tibiae of mice were removed and freed of muscles and tendons. The bones were placed in 70% ethanol for 2 min and subsequently washed in PBS. Both bone ends were cut and cells were flushed from the bones under sterile conditions with 2 mL of complete medium. Cell suspensions were washed and resuspended in complete medium. Absolute leukocyte counts were obtained using a Neubauer chamber using Turk solution (0.01% gentian violet in 3% glacial acetic acid) by optical microscopy.
Cell cultures with ATRA in vitro
Cells suspensions obtained from immunosuppressed (IS) spleens and BM were supplemented with low concentrations of GM-CSF (10 ng/mL) to stimulate granulocyte and monocyte precursors to proliferate and survive in culture. Splenic and BM cell cultures from IS mice were treated with ATRA (10 mM, IS/ þA) or were left untreated (IS/ÀA).
Flow cytometric studies
The main different populations present in the spleen and BM were studied using flow cytometry. 1 Â 10 6 cells were incubated with specific rat antimouse antibodies conjugated with different fluorochromes: Phycoerythrin (PE)-CD34, -F4/80, -Gr-1; fluorescein isothiocyanate (FITC)-CD11c; Phycoerythrin-Cyanine 5 (PE-Cy5-Gr-1, -CD31. Cells were washed and resuspended in paraformaldehyde 0.5%. The percentage of positive cells was determined among 70,000 events. The absolute number of the specific subpopulations was calculated as follows: (absolute total leukocyte cell count Â percentage obtained by flow cytometry)/100.
Apoptosis
The percentage of hematopoietic precursors (CD34þ) undergoing apoptosis was measured by flow cytometry using FITC-Annexin V (AnV), and anti-CD34-PE in cell suspensions obtained from the spleen and BM after 24 h of ATRA addition. AnV staining was performed using a commercial kit according to manufacturer's instructions. The absolute number of the apoptotic cells was calculated as follows: (absolute total leukocyte cell count Â percentage obtained by flow cytometry)/100.
Colony formation unit (CFU) assay
BM and splenic cells were plated in 0.1% Bacto agar in Iscove modified Dulbecco medium containing penicillin-streptomycin, 20% FCS, 20% glutamine, and 100 ng/mL of recombinant mouse granulocyte-macrophage colonystimulating factor (GM-CSF). They were added to six-well plates with 8 Â 10 5 BM cells and 1 Â 10 6 spleen cells per well. The plates were incubated at 378C in 5% CO 2 for 7 days to form a semisolid agar allowing granulocyte-monocytes colonies to grow and differentiate. Colonies (>40 cells) were scored by scanning the whole Petri dishes using an inverted microscope with phase contrast with Â20 magnification. To obtain the colonies area, pictures were taken with Â40 magnification and the areas calculated using the Fiji software program (22) .
Proliferation assays
5 Â 10 5 splenic and BM cells were seeded in 96-well plates with GM-CSF (10 ng/mL) for 48 h at 378C in 5% CO 2. Then 0.5 mCi/well of 3 H-thymidine was added and incubated for another 20 h. After that cells were harvest and scintillation fluid was added to the vials (2 mL/disc) and the radioactivity was measured using a beta-counter. For T lymphocyte proliferation assays, suspensions from spleen were obtained and resuspended in RPMI-1640, 10% FCS, 0.1% 2-mercapoethanol, 1% L-glutamine, and 1% antibiotic-antimycotic. Lymphocyte counts were determined with a Neubauer chamber using Turk solution. Moreover, CD3 ) for all groups were seeded in 96-well plates in triplicates in the presence or absence of Concanavalin A (Con A, 5 mg/mL) for 48 h at 378C in 5% CO 2 . Then 0.5 mCi/well of 3 H-thymidine was added and incubated for another 20 h and proceeded as previously described to measure the incorporation of 3 H-thymidine.
Gr-1 depletion
Spleen suspensions (5 Â 10 6 cells) were incubated with an anti-Gr-1 mAb for 30 min at 48C and then washed. Depletion was subsequently performed by incubating with magnetic beads according to manufacturer's instructions. The cell depleted fraction showed less than 2% of Gr-1þ cells as assessed by flow cytometry.
Intracellular inducible nitric oxide synthase (iNOS) determination
Twenty-four hours after Con A addition to the cultures, cells were collected with trypsin-0.5% EDTA, washed and counted with Turk solution by optic microscopy. Then, cells were incubated with PE-CD11b and PE-Cy5-Gr-1 antibodies for 30 min, washed and fixed with paraformaldehyde 0.05%. Cells were subsequently treated with triton X-100 (0.25%) for 15 min, blocked with 3% BSA for 1 h and stained with an anti-nitric oxide synthase (iNOS) antibody conjugated to FITC for 30 min. In all cases, isotype-matched antibodies were assayed in parallel and fluorescence was determined by flow cytometry on 100,000 events of each sample. The percentage of iNOSþ cells within the Gr-1þ CD11bþ population was determined and the absolute number of the iNOSþ Gr-1þ CD11bþ populations was calculated as follows: (absolute cell count Â percentage obtained by flow cytometry)/100.
Reactive oxygen species (ROS) determination
After 24 h of Con A addition to the cultures, cells were collected with trypsin-0.5% EDTA, washed and counted using Turk solution by optic microscopy. To determine the production of reactive oxygen species (ROS), dihydrorhodamine (DHR)-123 (Sigma) was used. Cells were incubated with a PE-Cy5-Gr-1 antibody and 1 mM of DHR-123 for 15 min at 378C. Upon ROS generation a brightly fluorescent FL-1 product is produced, which was detected by flow cytometry. The percentage of DHRþ cells within the Gr-1þ population was determined and the absolute number of the DHRþ Gr-1þ populations was calculated as follows: (absolute cell count Â percentage obtained by flow cytometry)/100.
Histology
The spleens of all sacrificed animals were fixed in 10% buffered formalin and embedded in paraffin. Semiserial cuts were performed for hematoxylineosin staining.
Statistics
For in vivo experiments, comparisons between multiple groups (Control, IS, and ISþA) were performed using one-way ANOVA, applying the correction of Bonferroni with the GraphPad Prism 5.0 software. For in vitro experiments, comparisons between cells obtained from IS mice left untreated (IS/ÀA) or treated with ATRA (IS/þA) were performed using a two-tailed paired t test. In all cases, P <0.05 was considered significant.
RESULTS
ATRA decreases the number of hematopoietic CD34R precursors in a murine model of LPS immunosuppression
To explore the capacity of ATRA to modify the number of CD34þ progenitors in LPS-induced immunosuppression, mice were daily inoculated with LPS (IS), and ATRA was administered concomitantly with LPS (ISþA). Cells obtained from the BM and the spleens were used because the spleen in adult mice, in contrast to humans, is both a hematopoietic and a secondary lymphoid organ (23) . The percentage of CD34þ cells was determined by flow cytometry and the absolute number was calculated considering the total leukocyte count as detailed in Materials and Methods. As Figure 1 shows, the IS group presented an increased number of hematopoietic CD34þ precursors in both the spleen and BM compared with the Control group. The treatment with ATRA in IS mice (ISþA) decreased the number of this population in both organs compared with the IS group. Administration of ATRA alone had no effect on the number of CD34þ cells compared with the Control group (data not shown). These results show the ability of ATRA to decrease the expansion of hematopoietic precursors in LPS-immunosuppressed mice.
ATRA decreases hematopoietic precursor proliferation in LPS immunosuppression
Taking into account the decrease in CD34þ cells observed in IS mice treated with ATRA, we performed in vitro cultures incubating splenic and BM cells from IS mice with or without ATRA to study the cellular mechanisms by which ATRA decreased the expansion of hematopoietic CD34þ precursors in LPS-induced immunosuppression.
As reported by other authors ( [24] and own unpublished results), we observed that cells, especially myeloid cells, do not survive more than 3 days without the presence of cytokines in culture (data not shown). Therefore, for all in vitro approaches we supplemented cell cultures with low concentrations of recombinant mouse GM-CSF to prevent unspecific cell death and, additionally, to favor granulocytic-macrophage myeloid precursor growth and proliferation. This led us to explore whether ATRA could modulate the growth/proliferation of CD34þ myeloid progenitors. First, we performed a colony forming unit (CFU) assay using semisolid agar with GM-CSF, which allows the evaluation of the quantity and characteristics of colonies generated exclusively by CD34þ cells after 7 days (14) . As shown in Figure 3A , the number of CFU decreased when IS cells from BM and spleen were treated with ATRA. Moreover, the area of the colonies was also lower in the presence of ATRA (Fig. 3B) . These results suggest that ATRA is modulating not only the number of myeloid precursors capable of generating colonies but also their ability to proliferate. To further confirm if ATRA is affecting the proliferation of hematopoietic precursors, a proliferation assay was performed measuring the incorporation of 3 H-thymidine after 72 h of ATRA addition in splenic and BM cells in suspension obtained from IS mice. Supporting the CFU assay results, the addition of ATRA decreased the incorporation of 3 H-thymidine in both hematopoietic organs (Fig. 3C) .
ATRA administration to LPS-immunosuppressed mice affects hematopoietic precursor proliferation
To extrapolate the effects observed in IS BM and splenic cultures treated with ATRA, mice were given ATRA concomitantly with LPS inoculation and CFU assays in the presence of GM-CSF were performed with cells obtained from BM and spleen of mice. As depicted in Figure 4A , administration of ATRA to mice (ISþA group) was able to reduce the number of CFU compared with the IS group, reaching values similar to those observed in the Control group, both in spleen and BM. Furthermore, the area of the colonies of ISþA mice was lower compared with IS mice (Fig. 4B) . Moreover, incorporation of 3 H-thymidine in cells obtained from the spleen and BM from ISþA mice supplemented with GM-CSF in culture decreased compared with the IS group (Fig. 4C) .
Altogether, the in vitro and in vivo results indicate that the mechanism by which ATRA decreases the number of hematopoietic CD34þ precursors is by reducing their cellular proliferation.
Administration of ATRA to IS mice decreased the generation of immature myeloid-derived suppressor cells (MDSC) and restored T lymphocyte proliferation MDSC are an immature myeloid cell population that are increased in late phases of sepsis playing a key role in the inhibition of the T lymphocyte proliferation observed in IS mice (9) . Moreover, based on the effects of ATRA in the decrease of immature cell proliferation, our next objective was to study if this drug was able to decrease the number of MDSC in IS mice and, as a result, modulate the impaired T cell proliferation in LPS-derived immunosuppression. Mouse MDSCs are identified by the co-expression of CD11b, Gr-1, and the immaturity marker CD31 on their cell surface (25) . As the spleen in adult mice is both a hematopoietic and a secondary immune organ, where immunological responses are initiated, we analyzed the presence of MDSC in the spleen of IS mice and their modulation by ATRA. Figure 5A shows that IS mice had an increment in the number of MDSC (Gr-1þ CD11bþ CD31þ) compared with the Control group and that the administration of ATRA (ISþA) was able to decrease this number. To evaluate whether this decrease was associated with a lower MDSC-mediated T cell suppressive function, we performed T cell proliferation assays from splenic cells measuring the incorporation of 3 H-thymidine using Concanavalin A (Con A) as a specific T cell mitogen. As shown in Figure 5B , T cell proliferation was decreased in IS mice compared with the Control group. Depletion of Gr-1þ cells from IS cell suspensions restored T cell proliferation to Control levels, indicating that MDSC in IS mice are responsible for the observed T cell proliferation inhibition. Additionally, treatment with ATRA to IS mice was able to restore the inhibited T cell proliferation, indicating that the lower number of MSDC observed by treatment with ATRA in IS mice is related to a reduced inhibitory function. Mice treated only with ATRA showed numbers of MDSC and levels of T cell proliferation similar to Control mice (data not shown).
It is known that the correct architecture of secondary lymphoid organs is necessary for an efficient initiation of adaptive immune responses (26) . Therefore, we examined the spleen's histology to study the effect of ATRA on the histological structure of this organ in the different groups. Figure 5C shows that the white pulp from spleens from Control mice had normal periarteriolar lymphoid sheaths (PALS), follicles, and marginal zones. Splenic cords and venous sinuses were also seen in the red pulp normal. However, the white pulp structures from IS mice were smaller and with an irregular shape; this shrinkage was mainly due to the depletion of lymphocyte populations in the outer PALS, the follicle, and the marginal zone. Additionally, the red pulp was relatively enlarged due to a decrease in all white pulp cellular components. Surprisingly, the spleens of IS animals treated with ATRA showed a partially restored histology. The white pulp structures reassumed their size and shape in an irregular fashion; some of the animals showed complete and normal cell populations while others showed an incomplete cell population lacking, mainly, the marginal zone. The red pulp seemed to be restored and the white/red pulp relationship was partially restored. Spleens from animals treated only with ATRA were similar to those of the Control group (data not shown). Altogether, these results indicate that ATRA is able to improve T cell functions in IS mice by decreasing MDCS cells and restoring the architecture of the spleen.
ATRA in vitro restored T cell proliferation and reduces the number of MDSC with suppressor activity from IS mice
To determine if ATRA directly affects the number of MDSC and in consequence, impacts on T cell proliferation, we performed in vitro assays adding ATRA to the cultures of splenic cells from IS mice. MDSC have been described to inhibit T cell proliferation by different mechanisms: causing an increase in the inducible form of iNOS that produces nitric oxide and releasing ROS (10) . Figure 6A shows that the addition of ATRA to IS cells in vitro caused an increase in T cell proliferation. This effect was accompanied by a decrease in the number of Gr-1þ iNOSþ and Gr-1þ DHRþ cell populations (Fig. 6 , B and C), indicating that ATRA can directly suppress the generation of MDSC and in consequence, improve T cell proliferation.
DISCUSSION
Vitamin A (retinol) is known to play an essential role in immunity and may be important for the optimal functioning of the innate and adaptive immune systems. Most of the effects of vitamin A are mediated by ATRA. Vitamin A deficiency has been associated with exacerbated immunodeficiency, reduced or unbalanced lymphocyte counts, and deregulated antibody production (1). Moreover, clinical trials have shown that vitamin A supplementation reduces morbidity and mortality from various infectious diseases, and numerous studies in animal models have confirmed the ability of vitamin A to prevent infections and to strengthen the immune system (27) . Secondary infections that develop due to post-sepsis immunosuppression are a major cause of death in septic patients (19) . In fact, in recent years, this loss of immune competence has been considered to be one of the main problems in late sepsis (28) . For that reason, many investigators consider that the effort to recover or preserve host immune functions will be the next major advance in the management of patients with sepsis.
The clinical importance of our study relies on finding strategies to restore the immune competence in patients who developed an immunosuppressive phase after sepsis and succumb to secondary opportunistic infections. Our work is focused on the study of this immunosuppressive phase, and our model mimics quite well this stage. Repetitive inoculation of LPS has been widely used to study the refractory to subsequent stimulation with LPS or bacteria associated to sepsis found at the cellular level. A similar loss of LPS reactivity, such as the one observed in LPS-immunosuppressed in [29] ). Persistent exposure to LPS in patients is possible, as evidenced by Torgersen et al. (30) , who reviewed post-mortem findings in 235 surgical intensive care unit patients admitted with a diagnosis of sepsis and found that, at death, a continuous septic focus was observed in 88.7% of patients who were treated for longer than 7 days. All experimental models have limitations, and even though no model reproduces all aspects of human sepsis, each experimental model allows studying at least those aspects of human sepsis that the model reproduces. Therefore, and considering the aspects presented above, we believe that our model is adequate to investigate and intervene on the immunosuppressive phase that patients may develop after a septic episode.
We have previously reported that administration of ATRA to LPS-immunosuppressed mice was able to restore immune competence, and this was in part mediated by the modulation of the inhibitory population of MDSC, which were inhibiting T cell proliferation in lymph nodes. Moreover, ATRA reverses the impaired LPS-induced primary humoral immune response (9) . In this work, our hypothesis was that ATRA could reduce MDSC generation by modulating myeloid lineage expansion, and therefore improve immunological competence. Our results are relevant to better understand the etiology of sepsis-induced immunosuppression. We found that ATRA abolished LPS-induced myelopoiesis, affecting the proliferation of CD34þ precursor cells, and in consequence, decreasing MDSC generation, having a direct impact on the improvement of immune competence. In this sense, we observed a restored T lymphocyte proliferation in IS mice treated with ATRA in concordance with a re-established histological architecture. This would be necessary for creating a supportive environment that facilitates the initiation of an adaptive immune response which is impaired in immunosuppressed septic patients. Moreover, we have previously shown that administration of ATRA to IS mice also restored the impaired antigen-specific humoral response (9) .
As ATRA has been reported to decrease the number of cell precursors by induction of apoptosis (31), differentiation to their mature counterparts (32) , or inhibiting their expansion (33), we also conducted experiments to discern the cellular mechanisms by which ATRA could be affecting MDSC generation. We found that ATRA interferes with myelopoiesis by decreasing the number of CD34þ myeloid precursor cells. This was also associated with a decrease in downstream populations derived from them, such as MDSC (Gr-1þ CD11bþ CD31þ). The decrease of CD34þ precursor cells was not mediated by apoptosis or by an increase in differentiation to more mature forms, such as macrophages (F4/80þ), neutrophils (Gr-1þ CD11bþ), or dendritic (CD11cþ) cells, as the numbers of these populations were similar or even lower in IS animals treated with ATRA compared with the IS alone. However, there was a consistent decrease in the proliferation of hematopoietic myeloid-committed precursors observed by the incorporation of 3 H-thymidine in the cultures supplemented with GM-CSF, and in the CFU that were decreased in both number and size. As this last assay implicates specific clone expansion of CD34þ cells (14) , the fact that the size of the colonies was reduced indicates that ATRA is lowering the proliferative rate of CD34þ precursors, resulting, in consequence, in a decreased number of daughter cells, including immature MDSC. Moreover, as ATRA is decreasing the number of early progenitor cells that will generate cell populations with suppressive activities in a pathological context, ATRA administration might be an interesting and fast strategy to reduce MDSC generation in their place of origin (hematopoietic organs), avoiding their expansion in later stages when the immunosuppressed scenario is highly developed. Additionally, as ATRA caused the same effect in vitro, when precursors were partially isolated from the IS context, this indicates that ATRA is directly affecting the capacity of cells to proliferate. The decreased proliferation in immature precursors results in a decreased downstream myeloid progeny.
The antiproliferative effects of ATRA could also be relevant for other immunosuppressive contexts, such as tumors, as it has also been reported that mouse granulocyte-macrophage progenitors isolated from tumor-bearing mice display strong suppressive properties, being capable of inhibiting polyclonal stimuli-and alloantigen-induced T cell proliferation (34) .
The results presented in this work showed for the first time the antiproliferative effects of ATRA on myeloid precursor cells in an IS-derived context. The importance of ATRA in an immunosuppressive scenario is related to MDSC and the regulation of their generation. In our model of immunosuppression, LPS inoculation caused an augmented demand for myeloid cells leading to increased proliferation of their precursors. This also brings about an increase in MDSC cells that negatively regulate lymphocyte responses. In this sense, the regulation of MDSC generation/differentiation has been shown to improve the immune function against tumors in animal models and patients (7). MDSC were recently described in septic patients (11) , and although their presence may imply a normal negative feedback to the huge pro-inflammatory response that is triggered in sepsis, it is also possible that these cells may also be involved, in part, in the susceptibility to infections that some patients develop (immunosuppressive phase).
Additional potential advantages of ATRA administration to post-sepsis immunosuppressed patients are supported by several observations. Reduced levels in serum and increased urinary excretion of retinol have been reported in critically ill patients with sepsis or septic shock (35) . As vitamin A deficiency damages the immunological response, it is possible that this deficiency renders patients more susceptible to secondary infections and contributes to immunosuppression after sepsis. Therefore, administration of ATRA may restore vitamin A deficiency, and controlling MDSC generation/expansion will improve the immunological state of these patients. The results of this study point to ATRA as a possible complementary treatment to reduce the early generation of MDSC, enabling septic patients to overcome the immunosuppressive phase.
